Amgen (NasdaqGS:AMGN) Q4 2025 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsCasey Capparelli - VP of Investor RelationsDavid Amsellem - Managing DirectorJames Bradner - EVP of Research and DevelopmentMurdo Gordon - EVP of Global Commercial OperationsPeter Griffith - CFORobert Bradway - CEOTerence Flynn - Managing DirectorUmer Raffat - Managing DirectorYaron Werber - Managing DirectorConference Call ParticipantsAlex Hammond - AnalystChris Schott - AnalystCourtney Breen - Senior Research Ana ...

Transcat (NasdaqGM:TRNS) Q3 2026 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsJohn Howe - Senior Director of Financial Planning and AnalysisLee Rudow - President and CEOTom Barbato - CFOConference Call ParticipantsGreg Palm - Senior Research AnalystMax Michaelis - Equity Research AnalystTed Jackson - Managing Director and Senior Research AnalystOperatorGood afternoon, ladies and gentlemen. Welcome to the Transcat third quarter fiscal year 2026 financial results conference call. As a remin ...

Amgen (NasdaqGS:AMGN) Q4 2025 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsCasey Capparelli - VP of Investor RelationsDavid Amsellem - Managing DirectorJames Bradner - EVP of Research and DevelopmentMurdo Gordon - EVP of Global Commercial OperationsPeter Griffith - CFORobert Bradway - CEOTerence Flynn - Managing DirectorUmer Raffat - Managing DirectorYaron Werber - Managing DirectorConference Call ParticipantsAlex Hammond - AnalystChris Schott - AnalystCourtney Breen - Senior Research Ana ...

Financial Data and Key Metrics Changes - Amgen delivered a 10% sales growth in 2025, with 14 products achieving over $1 billion in annual sales and 18 products reaching record sales [21][32] - Non-GAAP operating margin for the full year was 46%, with R&D spending increasing by 22% year-over-year to a record $7.2 billion [32][33] - Free cash flow generated for the full year was $8.1 billion, reflecting operational momentum and effective working capital management [33] Business Line Data and Key Metrics Changes - Repatha sales grew 36% year-over-year, surpassing $3 billion, driven by increased urgency in treating patients [21][22] - Evenity sales increased by 34% to $2.1 billion, with a 41% growth in the U.S. market [21][23] - Uplizna sales rose 73% year-over-year to $655 million, reflecting strong demand across all approved indications [24][25] - The rare disease portfolio grew 14% year-over-year to nearly $5.2 billion [24] - Tezspire sales grew 52% year-over-year to nearly $1.5 billion, positioning it as a leading therapy for severe uncontrolled asthma [28] Market Data and Key Metrics Changes - The U.S. market for Repatha is seeing improved patient access through broad formulary coverage and the launch of Amgen Now, a direct-to-patient program [22] - Evenity leads the bone builder segment with over 60% market share, with a significant opportunity remaining as nearly 90% of high-risk women remain untreated [23] - Uplizna is the most prescribed FDA-approved therapy for NMOSD in the U.S., supported by consistent new patient growth [25] Company Strategy and Development Direction - Amgen is focusing on six key growth drivers for 2026: Repatha, Evenity, Tezspire, rare disease, innovative oncology, and biosimilars [34][35] - The company is committed to advancing innovation in areas of high unmet medical need while maintaining rigorous financial discipline [38] - Amgen is leveraging AI across the value chain to enhance therapeutic discovery and development [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MariTide and its differentiated treatment for obesity and related conditions [6][10] - The company anticipates 2026 total revenues in the range of $37.0 billion to $38.4 billion, with non-GAAP earnings per share between $21.60 and $23 [34][36] - Management acknowledged potential challenges from increased competition and pricing pressures but remains optimistic about the overall growth trajectory [36][38] Other Important Information - Amgen's innovative oncology portfolio grew 11% year-over-year, generating $8.7 billion in full-year sales [30] - The company is advancing multiple late-stage programs and has completed five key regulatory approvals in 2025 [9][19] Q&A Session All Questions and Answers Question: Insights on MariTide and obesity portfolio - Management highlighted the development of MariTide across various indications and expressed confidence in competing broadly in the obesity field [42][44] Question: Dazodalibep for primary Sjögren's syndrome - Management confirmed that both phase 3 studies are fully enrolled and expect completion later this year, expressing confidence in the drug's potential [47][49] Question: Uplizna's market opportunity and usage - Management discussed the potential for increased awareness and diagnosis of IgG4-related disease, noting strong initial uptake of Uplizna [51][56] Question: Confidence in Uplizna's phase 3 study in CIDP - Management expressed optimism about Uplizna's unique mechanism of action and the potential to help patients with CIDP [60][63] Question: Repatha's prescription sources and market evolution - Management indicated that approximately 40% of Repatha prescriptions come from primary care, with expectations for growth following the VASILIS data promotion [72][74] Question: Tepezza and AMG 732 for TED - Management confirmed ongoing studies for Tepezza and expressed confidence in its strong evidence base and market position [77][80]

Core Insights - The biotechnology company reported a quarterly profit of $1.33 billion, which is attributed to higher revenue and lower net unrealized losses on equity investments [1] Financial Performance - Quarterly profit stands at $1.33 billion [1] - Earnings boost is linked to increased revenue [1] - There was a reduction in net unrealized losses on equity investments [1]

Q4 '25 Earnings Call February 3, 2026 Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance o ...

Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, driven by a 7% increase in drug sales and a lower tax rate. ...

Core Insights - Amgen Inc. is a leading biotechnology company engaged in innovative therapies and treatments, operating in a competitive landscape with peers like Biogen and Gilead Sciences [1] Investment Activity - Atlantic Union Bankshares Corp increased its investment in Amgen by 66.3% in Q3, now holding 17,698 shares valued at approximately $5 million, reflecting strong investor confidence [2] - Legacy Investment Solutions LLC and Evelyn Partners Investment Management LLP have acquired new stakes in Amgen, valued at around $27,000 and $32,000 respectively, indicating growing interest in the company's potential [3] - Quaker Wealth Management LLC increased its position in Amgen by 200% in Q2, further demonstrating the rising interest among investors [3] - Atle Fund Management AB reduced its holdings in Amgen by 42.2% in Q3, now owning 13,806 shares valued at approximately $3.9 million, showcasing varied investment strategies [4] Stock Performance - Amgen's stock is currently trading at $343.63, with a slight decrease of $1.16 or -0.34% today, and has experienced a 52-week high of $353.25 and a low of $261.43 [5] - The company maintains a solid market capitalization of approximately $185 billion, reinforcing its status as a key player in the biotechnology sector [5][6]

Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Feb. 3, 2026) - Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024. "Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portf ...

Atle Fund Management AB decreased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 42.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,806 shares of the medical research company’s stock after selling 10,088 shares during the period. Amgen makes up about 1.5% of Atle Fund Management AB’s holdings, making the stock its 26th biggest holding. Atle Fund Management AB’s holdings in Amgen were worth $3,896,000 at the end of the most recent ...